rsv arexvy - Search News

News

GSK, RSV and European Medicines Agency

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial

· 2d · on MSN

GSK applies to EU regulator for expanded use of RSV vaccine

· 2d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

STAT2d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Pharmabiz1d

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results